Bank of New York Mellon’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

Bank of New York Mellon’s Portfolio PNT Stock Details PNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-332,610	Closed	-$2.22M	–	4411
2023 Q3	$2.22M	Buy	332,610 +3,595	+1%	+$29.9K	﹤0.01%	2757
2023 Q2	$2.98M	Buy	329,015 +80,275	+32%	+$708K	﹤0.01%	2611
2023 Q1	$1.81M	Sell	248,740 -6,989	-3%	-$51.8K	﹤0.01%	2856
2022 Q4	$1.86M	Buy	255,729 +30,076	+13%	+$223K	﹤0.01%	2895
2022 Q3	$1.74M	Buy	225,653 +21,159	+10%	+$180K	﹤0.01%	2932
2022 Q2	$1.39M	Buy	204,494 +175,663	+609%	+$1.34M	﹤0.01%	3039
2022 Q1	$230K	Hold	28,831	–	–	﹤0.01%	4167
2021 Q4	$161K	Hold	28,831	–	–	﹤0.01%	4336
2021 Q3	$222K	Buy	+28,831	New	+$263K	﹤0.01%	4171

Other funds holding PNT

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Bank of New York Mellon's PNT Position: Q4 2023 in Review

Bank of New York Mellon sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q4 2023, closing a stake of 332,610 shares — an estimated $2.22M sold.

Bank of New York Mellon first reported a position in PNT in Q3 2021 and held it in 9 quarters. The position peaked at $2.98M in Q2 2023. 1 fund tracked by Wall St. Rank holds PNT as of Q4 2023.

Bank of New York Mellon reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Bank of New York Mellon sold 332,610 POINT Biopharma Global Inc. Common Stock shares in Q4 2023, an estimated $2.22M.
Bank of New York Mellon first reported a position in POINT Biopharma Global Inc. Common Stock in Q3 2021 and held it in 9 quarters.
Bank of New York Mellon's POINT Biopharma Global Inc. Common Stock position peaked at $2.98M in Q2 2023.
1 fund tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q4 2023.

Based on Bank of New York Mellon's 13F filing for Q4 2023, filed 29 Jan 2024.